Bexagliflozin (Brenzavvy) and dapagliflozin (Farxiga) induced similar HbA1c reductions over 24 weeks in a head-to-head phase III trial of the SGLT2 inhibitors in Chinese adults with type 2 diabetes on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback